Clinical Trials
22 trialsNCT07347600 2026-05-18
reaINAVO
Hoffmann-La Roche
Recruiting
NCT05022342 2026-02-23
SPEAR
Novartis
Completed
NCT04967248 2025-12-04
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting
Novartis
Terminated
NCT07096024 2025-08-28
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
Pfizer
Completed
NCT06734533 2024-12-16
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
Hunan Cancer Hospital
Recruiting
NCT06525675 2024-12-13
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
MedSIR
Completed
NCT06341283 2024-05-10
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
The Affiliated Hospital of Qingdao University
Not yet recruiting
NCT04778982 2023-07-17
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Terminated
NCT04916509 2023-06-06
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
Pfizer
Completed
NCT02753686 2023-02-15
Treat ER+ight
Novartis
Completed
NCT05427617 2022-06-22
ACTDNAGLT
Hunan Cancer Hospital
Completed
NCT05000736 2022-04-29
CAPACITY
ChineseAMS
Unknown
NCT02909361 2022-04-20
Fulvestrant 500mg in Patients With Advanced Breast Cancer
Fudan University
Unknown
NCT05140655 2021-12-01
Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-
Dr. Reddy's Laboratories SAS
Unknown
NCT04852081 2021-04-21
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Blokhin's Russian Cancer Research Center
Unknown
NCT04524728 2020-08-24
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
Istituti Clinici Scientifici Maugeri SpA
Completed
NCT04289974 2020-02-28
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
ChineseAMS
Unknown
NCT04258163 2020-02-10
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Completed
NCT03925233 2019-04-24
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Unknown
NCT01509625 2016-06-01
EFFICACY
Hospital Clinico Universitario San Cecilio
Completed
NCT01399086 2012-03-13
Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer
Hellenic Oncology Research Group
Completed
NCT00660803 2010-01-21
Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
AstraZeneca
Completed